# Jason Gardner

> Jason Gardner is the CEO of Ampersand Biomedicines and a CEO-Partner at Flagship Pioneering, where he leads a Boston-area biotech programming biologic medicines that act only at the site of disease. A Cambridge- and Oxford-trained scientist turned operator, he previously co-founded and ran Magenta Therapeutics through its IPO and spent years building GSK's Regenerative Medicine Unit. He is betting that the next generation of drugs will not just be potent but precise - going exactly where they are needed and nowhere else.

- **Role:** CEO at Ampersand Biomedicines; CEO-Partner at Flagship Pioneering
- **Organizations:** Ampersand Biomedicines, Flagship Pioneering, Magenta Therapeutics, GSK, Progenics Pharmaceuticals, Chiron Corporation
- **Nationality:** British
- **Education:** B.A. and M.A. in Natural Sciences (Biochemistry), University of Cambridge, D.Phil. in Molecular Medicine, University of Oxford, Postdoctoral fellowship (hematopoietic stem cells), Harvard Medical School
- **Known for:** Co-founded and led Magenta Therapeutics through a successful IPO, Built and led GSK's Regenerative Medicine Unit from the ground up, Established GSK partnerships with the Harvard Stem Cell Institute and the Telethon Institute for Gene Therapy

## Career timeline

- **Early career** — Principal Scientist at Chiron Corporation
- **Early career** — Associate Director at Progenics Pharmaceuticals
- **GSK years** — Held roles of increasing responsibility at GSK, including head of the Center of Excellence for External Drug Discovery, overseeing 40+ programs across five therapeutic areas
- **GSK years** — Head of R&D in Boston; created and led GSK's Regenerative Medicine Unit; forged partnerships with Harvard Stem Cell Institute and the Telethon Institute for Gene Therapy
- **2015-2022** — Co-Founder, President and CEO of Magenta Therapeutics; advanced programs into the clinic, completed an IPO, scaled past 100 employees
- **2023** — Appointed CEO of Ampersand Biomedicines and CEO-Partner at Flagship Pioneering (August 2023)
- **2025** — Ampersand raised a $65M Series B (bringing total funding to roughly $115M)
- **2026** — Ampersand advanced AMP-220, a gut-targeted IL-22 AND-Body therapeutic, and announced a Genethon collaboration on tissue-specific AAV vectors

## Achievements

- Co-founded and led Magenta Therapeutics through a successful IPO
- Built and led GSK's Regenerative Medicine Unit from the ground up
- Established GSK partnerships with the Harvard Stem Cell Institute and the Telethon Institute for Gene Therapy
- Oversaw 40+ drug programs across five therapeutic areas at GSK's Center of Excellence for External Drug Discovery
- Raised a $65M Series B for Ampersand Biomedicines in 2025

## Latest updates

- **2026-05** — Ampersand announced a collaboration with Genethon to develop novel AAV vectors with enhanced tissue specificity for gene therapies.
- **2026-04** — Ampersand shared preclinical data on AMP-220, a gut-targeted IL-22 AND-Body therapeutic.
- **2025-03** — Ampersand closed a $65M Series B financing round.

## Links

- Website: https://ampersand.bio
- LinkedIn: http://www.linkedin.com/in/jason-gardner-2a568957
- Twitter/X: https://x.com/jasonbiotech1
- YouTube: https://www.youtube.com/watch?v=g8pYAyChzPs

---

Profile page: https://yespress.io/jason-gardner
Published by YesPress — https://yespress.io
Last updated: 2026-07-01